Nautilus Biotechnology (NAUT) Prepaid Assets (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Prepaid Assets of $3.6 million for Q2 2026, up 21.33% sequentially from $3.0 million in Q1 2026, and up 26.05% YoY from $2.9 million in Q2 2025.
Nautilus Biotechnology (NAUT) Prepaid Assets (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Prepaid Assets for 7 years, with the latest figure at $3.6 million in Q2 2026.
- Quarterly Prepaid Assets rose 26.05% year-over-year to $3.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.6 million (up 26.05% YoY) and the FY2025 annual result came in at $2.6 million, down 12.82% from the prior year.
- Prepaid Assets rose to $3.6 million in Q2 2026 per NAUT's latest filing, from $3.0 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $4.1 million in Q2 2022 and troughed at $2.6 million in Q4 2025.
- A 5-year average of $3.2 million and a median of $3.2 million in 2022 frame the typical range for Prepaid Assets.
- The widest YoY moves for Prepaid Assets: up 1062.32% in 2022, down 33.28% in 2022.
- Over 5 years, Prepaid Assets stood at $2.7 million in 2022, then rose by 24.87% to $3.4 million in 2023, then slipped by 14.21% to $2.9 million in 2024, then fell by 12.82% to $2.6 million in 2025, then jumped by 40.59% to $3.6 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $3.6 million, $3.0 million, and $2.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Nautilus Biotechnology | 120.16 Mn | 120.16 Mn | 175,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.60 Mn |
| Mar 31, 2026 | 2.96 Mn |
| Dec 31, 2025 | 2.56 Mn |
| Sep 30, 2025 | 2.90 Mn |
| Jun 30, 2025 | 2.85 Mn |
| Mar 31, 2025 | 2.79 Mn |
| Dec 31, 2024 | 2.93 Mn |
| Sep 30, 2024 | 3.60 Mn |
| Jun 30, 2024 | 3.49 Mn |
| Mar 31, 2024 | 3.73 Mn |
| Dec 31, 2023 | 3.42 Mn |
| Sep 30, 2023 | 3.50 Mn |
| Jun 30, 2023 | 3.41 Mn |
| Mar 31, 2023 | 3.14 Mn |
| Dec 31, 2022 | 2.74 Mn |
| Sep 30, 2022 | 3.25 Mn |
| Jun 30, 2022 | 4.11 Mn |
| Mar 31, 2022 | 2.95 Mn |
| Dec 31, 2021 | 3.49 Mn |
| Sep 30, 2021 | 4.88 Mn |